Skip to main content
Equibles
CTSO logo

CTSO · Cytosorbents Corp · Metrics

Track CTSO — free

Use CTSO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTSO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.87 -0.50 (-9.31%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“approximately $4.4 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$15.30M
Shares
3.14M
Volume · Nov 13 11.02K Avg daily vol (48 sessions) 39.07K

CTSO metrics

79 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.87
Market cap
$15.30M

Price action

23 metrics
Price change (1W)
+1.5%
Price change (30D)
+59.2%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$16.74
52-week low
$3.06
Change from 52-week high
-70.9%
Change from 52-week low
+59.2%
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
506.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
49.2
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
39,070
Relative volume
0.3
Average dollar volume
$181,977

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
3.14M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 132.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 243.2%
P / book
—
FCF yield
-60.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-119.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.4×
reciprocal yield 70.1%
EV / revenue historical average (5Y)
2.0×
reciprocal yield 51.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-12

Profitability

9 metrics
Gross margin
71.6%
Operating margin
-34.7%
Trailing 12 months
Net margin
-48.9%
Gross profit (TTM)
$26.65M
Operating profit (TTM)
−$12.93M
Net income (TTM)
−$18.21M
Trailing 12 months
Diluted EPS (TTM)
$-5.80
FCF margin
-25.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$12.08
Gross profit per diluted share (TTM)
$8.66
Operating profit per diluted share (TTM)
$-4.23
EBITDA per diluted share (TTM)
$-4.38
Net income per diluted share (TTM)
$-5.94
Operating cash flow per diluted share (TTM)
$-3.03
Free cash flow per diluted share (TTM)
$-3.08
Capital expenditures per diluted share (TTM)
$0.05
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.75
Book value per share
$1.88

Growth

11 metrics
Revenue growth YoY
+0.2%
Year over year
Net income growth YoY
-326.9%
Revenue (TTM)
$37.22M
Trailing 12 months
EPS growth YoY
-333.3%
Shares change YoY
-6.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.2%
Revenue CAGR (5Y)
-2.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-48.0%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$11.77M
Free cash flow (TTM)
−$9.30M
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$12.83M
Latest balance sheet
Cash & equivalents
$4.41M
Total assets
$37.96M
Total debt
$17.24M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$9.15M
Capital expenditures (TTM)
$150,000
R&D (TTM)
$9.72M
SG&A (TTM)
$34.16M
Stock compensation (TTM)
$2.29M
R&D / revenue
—
Stock compensation / revenue
6.1%

Ownership (13F)

9 metrics
13F filers
50
13F filer change QoQ
0
Institutional ownership
25.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
3.5%
Private-fund adviser ownership
3.2%
Active holders' share change QoQ
-0.8%
Holder tenure
19.4
Price vs estimated holder cost
-86.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.0%

Short interest

3 metrics
Short interest
4.3%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
$120,435
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1175151 CUSIP 23283X305 13F (30d) 34 filings 25 filers Visit website Investor relations